Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents

NCT04250116 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

960

Enrollment

OTHER

Sponsor class

Conditions

Atrial Fibrillation

Interventions

DRUG: NOAC monotherapy
DRUG: Dual antithrombotic therapy with NOAC and clopidogrel

Sponsor

Yonsei University